ArticleFrontiers in immunology2026
Diagnostic value of inflammatory biomarkers of IgA vasculitis based on Olink technology.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Abdominal IgA vasculitis (IgAV) often presents with nonspecific symptoms, complicating accurate diagnosis. There is an urgent need for plasma biomarkers that can reliably distinguish affected patients from healthy individuals. Objective: To identify and validate plasma inflammatory biomarkers for abdominal IgAV using Olink technology. Methods: Fasting plasma samples were collected from 10 IgAV patients with abdominal involvement and 10 healthy controls. The Olink Target 96 Inflammation panel was employed to quantify 92 inflammation-related proteins, followed by enzyme-linked immunosorbent assay (ELISA) validation in an expanded cohort. Results: Twenty-two cytokines were significantly upregulated in IgAV patients compared to controls. Among these, IL-8, OSM, TGF-α, TNFSF-14, and HGF exhibited strong diagnostic potential. In the validation cohort, IL-8, OSM, and TNFSF-14 remained significantly elevated. The combined ROC AUC for these three markers was 0.922 (95% CI: 0.823-1.021), with a sensitivity of 83.3% and specificity of 90.0%, notably outperforming any single marker. Decision curve analysis confirmed the clinical utility of this combined panel. Functional enrichment analysis revealed that these proteins are closely linked to inflammatory pathways, including cytokine-cytokine receptor interaction and the NF-κB signaling cascade. Conclusion: IL-8, OSM, and TNFSF-14 represent promising plasma biomarkers for abdominal IgAV. Our findings offer novel insights into disease pathogenesis and indicate a more accessible diagnostic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.